Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884455 | 1.00 | CAPN1 (0.61) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL3882611 | 1.00 | CAPN1 (0.61) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL3882948 | 0.98 | CAPN1 (0.63) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL13480197 | 0.89 | TDP1 (0.58) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL12418238 | 0.87 | TDP1 (0.65) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL7207224 | 0.86 | TDP1 (0.69) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL28676999 | 0.85 | CA1 (0.56) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL15858238 | 0.85 | TDP1 (0.63) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL31108264 | 0.85 | CA1 (0.56) | CAPN1TDP1CA1CA2MEN1 | |
| SCHEMBL20922191 | 0.84 | MAOA (0.55) | CAPN1TDP1CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | PROGEN PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7491849-B2 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050080144-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-1436246-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | SLIL Biomedical Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033455-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | SLIL BIOMEDICAL CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080144-A1 | Oligoamine compounds and derivatives thereof for cancer therapy | THOP1, OAT, DUT | CAPN1 3206/4885TDP1 659/4885CA1 4403/4885 |
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | THOP1, OAT, DUT | CAPN1 3206/4885TDP1 659/4885CA1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.